• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

严重急性呼吸综合征冠状病毒 2 疫苗接种用于炎症性肠病的儿科患者。

Severe Acute Respiratory Syndrome Coronavirus 2 Vaccination for Paediatric Patients With Inflammatory Bowel Diseases.

机构信息

Paediatric Gastroenterology Unit, UZ Brussels, VUB, Brussels, Belgium.

Department of Paediatrics, University Hospital Motol, Prague, Czech Republic.

出版信息

J Pediatr Gastroenterol Nutr. 2021 Oct 1;73(4):433-436. doi: 10.1097/MPG.0000000000003260.

DOI:10.1097/MPG.0000000000003260
PMID:34347673
Abstract

In this communication, the members of the Porto group (the European Society for Paediatric Gastroenterology, Hepatology and Nutrition [ESPGHAN], inflammatory bowel diseases [IBD] working group) provide the current available evidence regarding vaccination of children and young adolescents with IBD against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Our intent is to help provide meaningful answers to the concerns that parents and adolescents may have.

摘要

在本通讯中，波尔图小组（欧洲儿科学会胃肠病学、肝病学和营养学分会[ESPGHAN]，炎症性肠病[IBD]工作组）提供了目前关于患有 IBD 的儿童和青少年接种严重急性呼吸综合征冠状病毒 2（SARS-CoV-2）疫苗的可用证据。我们的目的是帮助为家长和青少年的担忧提供有意义的答案。

相似文献

1
Severe Acute Respiratory Syndrome Coronavirus 2 Vaccination for Paediatric Patients With Inflammatory Bowel Diseases.严重急性呼吸综合征冠状病毒 2 疫苗接种用于炎症性肠病的儿科患者。
J Pediatr Gastroenterol Nutr. 2021 Oct 1;73(4):433-436. doi: 10.1097/MPG.0000000000003260.
2
Corona Virus Disease 2019 and Paediatric Inflammatory Bowel Diseases: Global Experience and Provisional Guidance (March 2020) from the Paediatric IBD Porto Group of European Society of Paediatric Gastroenterology, Hepatology, and Nutrition.2019 年冠状病毒病与小儿炎症性肠病：欧洲小儿胃肠病学、肝病学和营养学学会小儿炎症性肠病波尔图小组的全球经验和临时指南（2020 年 3 月）。
J Pediatr Gastroenterol Nutr. 2020 Jun;70(6):727-733. doi: 10.1097/MPG.0000000000002729.
3
Pediatric Gastroenterology and Hepatology in Italy before and after the COVID-19: Lessons learned and management changes by SIGENP.意大利儿科胃肠病学和肝脏病学在 COVID-19 前后：SIGENP 吸取的经验教训和管理变化。
Ital J Pediatr. 2023 Jan 26;49(1):15. doi: 10.1186/s13052-023-01418-7.
4
[SARS-CoV-2 Vaccination for Adult Patients with Inflammatory Bowel Disease: Expert Consensus Statements by KASID].[成人炎症性肠病患者的新型冠状病毒2型疫苗接种：韩国炎症性肠病学会专家共识声明]
Korean J Gastroenterol. 2021 Aug 25;78(2):117-128. doi: 10.4166/kjg.2021.110.
5
The Impact of Severe Acute Respiratory Syndrome Coronavirus Type 2 on Children With Liver Diseases: A Joint European Society for Pediatric Gastroenterology, Hepatology and Nutrition and Society of Pediatric Liver Transplantation Position Paper.严重急性呼吸综合征冠状病毒 2 型对肝病儿童的影响：欧洲儿科胃肠病学、肝病学和营养学学会与儿科肝移植学会联合立场文件。
J Pediatr Gastroenterol Nutr. 2022 Jan 1;74(1):159-170. doi: 10.1097/MPG.0000000000003339.
6
SARS-CoV-2 vaccination for patients with inflammatory bowel disease: a British Society of Gastroenterology Inflammatory Bowel Disease section and IBD Clinical Research Group position statement.炎症性肠病患者的 SARS-CoV-2 疫苗接种：英国胃肠病学会炎症性肠病分会和 IBD 临床研究小组立场声明。
Lancet Gastroenterol Hepatol. 2021 Mar;6(3):218-224. doi: 10.1016/S2468-1253(21)00024-8. Epub 2021 Jan 26.
7
Clinical Genomics for the Diagnosis of Monogenic Forms of Inflammatory Bowel Disease: A Position Paper From the Paediatric IBD Porto Group of European Society of Paediatric Gastroenterology, Hepatology and Nutrition.临床基因组学在单基因炎症性肠病诊断中的应用：欧洲儿科学胃肠病学、肝病学和营养学协会波尔图儿科学 IBD 小组的立场文件。
J Pediatr Gastroenterol Nutr. 2021 Mar 1;72(3):456-473. doi: 10.1097/MPG.0000000000003017.
8
Impact of SARS-CoV-2 Vaccination on Inflammatory Bowel Disease Activity and Development of Vaccine-Related Adverse Events: Results From PREVENT-COVID.SARS-CoV-2 疫苗接种对炎症性肠病活动和疫苗相关不良事件发展的影响：来自 PREVENT-COVID 的结果。
Inflamm Bowel Dis. 2022 Oct 3;28(10):1497-1505. doi: 10.1093/ibd/izab302.
9
Humoral Immunogenicity After Vaccination Against SARS-CoV-2 Infection in Inflammatory Bowel Disease Patients Under Immunosuppressive Therapy: Should We Prioritize an Additional Booster Injection?免疫抑制治疗的炎症性肠病患者接种 SARS-CoV-2 疫苗后的体液免疫原性：我们是否应该优先考虑额外加强注射？
Inflamm Bowel Dis. 2023 Feb 1;29(2):268-273. doi: 10.1093/ibd/izac187.
10
Anti-SARS-CoV-2 Vaccination and Antibody Response in Patients With Inflammatory Bowel Disease on Immune-modifying Therapy: Prospective Single-Tertiary Study.抗 SARS-CoV-2 疫苗接种和免疫调节治疗的炎症性肠病患者的抗体反应：前瞻性单中心研究。
Inflamm Bowel Dis. 2022 Oct 3;28(10):1506-1512. doi: 10.1093/ibd/izab301.

引用本文的文献

1
Postvaccination Immunogenicity of BNT162b2 SARS-CoV-2 Vaccine and Its Predictors in Pediatric Inflammatory Bowel Disease.BNT162b2 疫苗接种后对儿童炎症性肠病患者的 SARS-CoV-2 免疫原性及其预测因素
J Pediatr Gastroenterol Nutr. 2023 Feb 1;76(2):e36-e44. doi: 10.1097/MPG.0000000000003661. Epub 2022 Nov 23.
2
Evaluation of Safety and Immunogenicity of BNT162B2 mRNA COVID-19 Vaccine in IBD Pediatric Population with Distinct Immune Suppressive Regimens.BNT162B2 mRNA新冠疫苗在采用不同免疫抑制方案的炎症性肠病儿科人群中的安全性和免疫原性评估。
Vaccines (Basel). 2022 Jul 11;10(7):1109. doi: 10.3390/vaccines10071109.
3
Safety of SARS-CoV-2 vaccination in patients with inflammatory bowel disease: A systematic review and meta-analysis.
新型冠状病毒疫苗在炎症性肠病患者中的安全性：系统评价和荟萃分析。
Dig Liver Dis. 2022 Jun;54(6):713-721. doi: 10.1016/j.dld.2022.03.005. Epub 2022 Mar 22.